Feature|Articles|May 15, 2026

FAQs: Presentation and evaluation of LUTS/BPH under the 2026 AUA guideline

Author(s)Hannah Clarke

These FAQs outline key AUA guideline recommendations on the presentation and evaluation of LUTS secondary to BPH.

On May 7, 2026, the American Urological Association (AUA) released its 2026 Management of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign Prostatic Hyperplasia (BPH) Guideline. The update includes 62 recommendations that reflect newly available clinical evidence, evolving medical therapies, and advances in minimally invasive and surgical treatment options. The guideline summary was published in The Journal of Urology as a 3-part series, and Part I addresses the initial presentation, evaluation, and initial management of patients with LUTS/BPH.1

“Lower urinary tract symptoms related to benign prostatic hyperplasia can significantly impact quality of life, and managing them requires thoughtful, evidence‑based care,” said Ramy Goueli, MD, MHS, chair of the Guideline, in a news release from AUA.2 The guideline emphasizes shared decision-making and individualized care, “recognizing that urinary symptoms may result from multiple contributing factors beyond prostate enlargement alone,” the AUA noted.

The following FAQs summarize the key recommendations on presentation and evaluation; a companion FAQ covers the medical and surgical management of LUTS/BPH.

1. Why does the guideline place such emphasis on evaluation and shared decision-making?

According to the guideline authors, non-neurogenic LUTS can be due to bladder, prostate, urethral, or other pathology.1 Bothersome LUTS is the main reason patients seek treatment and generally drives management decisions, which is why the guideline describes shared decision-making as playing a critical role in the initiation and escalation of treatment. In addition to patient history and physical examination, the Part I recommendations address the appropriate use of tests and patient counseling.

2. What evidence informs the guideline?

The systematic review that informs the guideline was based on searches in Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews through January 2025, with update searches conducted on December 15, 2025. Searches were limited to studies of medical therapies published since 2009 and surgical studies published since 2014 and were supplemented by reviewing the reference lists of relevant articles. Inclusion and exclusion criteria were based on the panel’s key questions and its populations, interventions, comparators, outcomes, timing, types of studies, and settings of interest. Evidence levels were assigned where possible.

3. What should the initial evaluation include?

In the initial evaluation of patients presenting with LUTS/BPH, clinicians should obtain a medical history, conduct a physical examination, use standardized symptom scores, and perform a urinalysis (Clinical Principle). These 4 elements form the core workup on which the remaining evaluation recommendations build.

4. Should PSA be checked at the initial visit?

Clinicians may obtain a prostate-specific antigen (PSA) level in patients with LUTS/BPH after engaging in shared decision-making (Expert Opinion). PSA testing is therefore an option to be discussed with the patient rather than a mandatory component of the initial evaluation.

5. When are post-void residual and uroflowmetry useful?

Clinicians may obtain a post-void residual (PVR) and/or uroflowmetry in patients with LUTS/BPH to evaluate for urinary retention or to exclude other disorders (Clinical Principle). These tests may also be offered during routine follow-up (Expert Opinion).

6. What is the role of urodynamic testing?

Clinicians may perform invasive or noninvasive pressure flow testing/urodynamic studies (UDS) to define bladder function when diagnostic uncertainty exists (Expert Opinion). Pressure flow testing/UDS, and/or cystoscopy, may also be offered if LUTS/BPH worsen during follow-up (Expert Opinion).

7. How should clinicians address the risk of progression and retention?

Clinicians should inform patients with LUTS/BPH of their risk factors for LUTS progression and retention and address those that are modifiable (Expert Opinion). For patients with multiple nonmodifiable risk factors, clinicians should consider BPH treatment (Expert Opinion).

8. What should initial counseling on treatment options cover?

Clinicians should counsel patients with LUTS/BPH on options for intervention, which can include behavioral/lifestyle modifications, medical therapy, or procedural interventions (Clinical Principle). The specific recommendations for medical therapy are reviewed in the companion FAQ on medical management of LUTS/BPH.

9. When should patients be re-evaluated after starting treatment?

Clinicians should evaluate patients with LUTS/BPH within 6 months after initiating treatment to assess response to therapy (Clinical Principle). Re-evaluation should include standardized symptom scores and evaluation of any adverse events to treatment.

10. What should happen if symptoms do not improve with treatment?

Among patients with LUTS/BPH who have undergone treatment and do not have symptom improvement, clinicians should pursue an alternative diagnosis and/or recommend an alternative treatment pathway (Clinical Principle). Pressure flow testing/UDS and/or cystoscopy may help clarify the picture when symptoms worsen during follow-up (Expert Opinion).

11. What testing is recommended before a procedural intervention?

Before procedural intervention, clinicians should obtain a PVR (Clinical Principle) and should use imaging studies to assess the volume and shape of the prostate (Clinical Principle). Clinicians may also perform a cystoscopy before the procedure (Clinical Principle).

____

REFERENCES

1. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation. J Urol. 0(0). doi:10.1097/JU.0000000000005097

2. American Urological Association Releases the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline. News release. American Urological Association. May 7, 2026. Accessed November 9, 2026. https://www.auanet.org/about-us/media-center/aua-press-center/aua-releases-the-management-of-luts-attributed-to-bph-guideline


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.